Caribou Biosciences, Inc
2929 7th Street
39 articles with Caribou Biosciences, Inc
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, today announced that co-founder Jennifer Doudna, Ph.D., has been awarded the 2020 Nobel Prize in Chemistry. In awarding the prize to Dr. Doudna, the Swedish Academy cited her contributions to science for the co-development of CRISPR-Cas9, a genome editing breakthrough which has revolutionized biomedicine. The prize was also a
9/14/2020It was a busy week for clinical trial updates. Here’s a look.
Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy
Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Dru
Caribou Biosciences, Inc., a leading CRISPR genome editing company, today announced the appointment of Cherry Thomas, MD, as Senior Vice President of Clinical Development. In this newly created position, Dr. Thomas will serve as Caribou’s clinical leader and oversee the advancement of the Company’s first allogeneic CAR-T cell therapy candidate, expected to start clinical trials later this year. “The experience and e
- Agreement enables Caribou to utilize MaxCyte's ExPERT® platform for its CRISPR gene-edited, allogeneic T cell therapy programs
Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA
Feb. 19, 2020 13:00 UTC BERKELEY, Calif. & RICHMOND, Calif.--( BUSINESS WIRE )-- Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic eng
Caribou Biosciences Announces New Methods to Harness Type I CRISPR-Cas Systems for Genome Engineering in Human Cells
Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced the publication of a new study demonstrating human genome engineering with Type I CRISPR-Cas systems.
Caribou Biosciences announces that JAMS panel issued Interim Award in the arbitration with Intellia Therapeutics
A three-member JAMS panel issued an Interim Award in the arbitration between Intellia Therapeutics, Inc. and Caribou Biosciences, Inc.
Oxford Nanopore Announces That It Has Entered Into a Non-exclusive Agreement With Caribou Biosciences for CRISPR-Cas9 Enrichment for Nanopore Sequencing
Technology enables targeted sequencing for rapid, precise DNA analysis on portable or large sequencers
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
The newly appointed members will work with current SAB members and Caribou co-founders Jennifer Doudna, PhD and Martin Jinek, PhD.
Dr. Sacks is an accomplished industry leader and oncology expert who has played a key role in the development and approval of several oncology therapeutics.
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
In the biotech world, only 7 to 9 percent of companies have women as their chief executives. Antiva BioSciences is a good example of how this problem is perpetuated.
6/26/2018The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives.
The U.S. Patent and Trademark Office (USPTO) granted Emmanuelle Charpentier, co-founder of ERS Genomics, the University of California and University of Vienna, their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
Caribou Biosciences, Inc. announced today that it has appointed Timothy F. Herpin, Ph.D. as its first Chief Business Officer.
CRISPR, Intellia, Caribou Biosciences And ERS Genomics Announce Appellate Brief Seeking Reversal Of U.S. Patent Board Decision On CRISPR/Cas9 Gene Editing